Su1862 GUSELKUMAB IMPROVES SYMPTOMS OF FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 3 QUASAR INDUCTION STUDY RESULTS AT WEEK 12
Axel Dignaß(Goethe University Frankfurt), Jessica R. Allegretti(Brigham and Women's Hospital), Gary R. Lichtenstein, Julián Panés(Hospital Clínic de Barcelona), David T. Rubin(University of California System), David Rowbotham(University of Auckland), Brian Bressler(University of British Columbia), Kuan‐Hsiang Gary Huang(Janssen (United States)), Miao Ye(Western University), Fang Gu(Sun Yat-sen University), Dwiti Pandya, Emese Mihály(Semmelweis University), Matthew Germinaro(Johnson & Johnson (United States)), Hongyan Zhang(Northwest A&F University), Cheng‐Long Han
Cited by 0
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
A Novel Integrated Method for Large-Scale Detection, Identification, and Quantification of Widely Targeted Metabolites: Application in the Study of Rice Metabolomics
|Molecular Plant|2013|1.9k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k